CELYAD SA/ADR (CYAD) Receives New Coverage from Analysts at William Blair

William Blair initiated coverage on shares of CELYAD SA/ADR (NASDAQ:CYAD) in a research report released on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating on the stock. William Blair also issued estimates for CELYAD SA/ADR’s FY2018 earnings at ($4.38) EPS, FY2019 earnings at ($4.20) EPS, FY2020 earnings at ($4.18) EPS, FY2021 earnings at ($3.44) EPS and FY2022 earnings at ($3.41) EPS.

“Celyad S.A. Using the Body’s “Natural Born Killers” in Solid and Liquid Tumors; Initiating With an Outperform Rating We are initiating coverage on Celyad with an Outperform rating and $53 fair value estimate.”,” the firm’s analyst commented.

CYAD has been the topic of a number of other reports. Zacks Investment Research cut shares of CELYAD SA/ADR from a hold rating to a sell rating in a research note on Monday, August 27th. ValuEngine upgraded shares of CELYAD SA/ADR from a sell rating to a hold rating in a research note on Monday, July 2nd. Finally, HC Wainwright initiated coverage on shares of CELYAD SA/ADR in a research note on Monday, July 2nd. They set a buy rating and a $45.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. CELYAD SA/ADR presently has an average rating of Buy and a consensus target price of $41.75.

Shares of NASDAQ CYAD opened at $28.10 on Tuesday. CELYAD SA/ADR has a fifty-two week low of $22.17 and a fifty-two week high of $59.05.

A number of large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. grew its holdings in CELYAD SA/ADR by 2.8% during the third quarter. Victory Capital Management Inc. now owns 621,162 shares of the company’s stock worth $16,374,000 after acquiring an additional 17,160 shares during the period. Stanley Laman Group Ltd. acquired a new position in CELYAD SA/ADR during the second quarter worth about $1,145,000. Millennium Management LLC acquired a new position in CELYAD SA/ADR during the second quarter worth about $582,000. Jane Street Group LLC grew its holdings in CELYAD SA/ADR by 168.9% during the first quarter. Jane Street Group LLC now owns 16,816 shares of the company’s stock worth $586,000 after acquiring an additional 10,562 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in CELYAD SA/ADR by 1,109.0% during the third quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after acquiring an additional 5,545 shares during the period. 7.01% of the stock is currently owned by hedge funds and other institutional investors.

CELYAD SA/ADR Company Profile

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Read More: What are the risks of holding treasury bonds?

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply